Immunological effects of anticancer therapy.

Slides:

Advertisements

Similar presentations

Tumour immunology & immunotherapy

Advertisements

Cancer immunology and immunotherapy. First an aside  Oncogenes and tumor suppressor genes.  Definitions anyone?  Oncogene –  Tumor suppressor gene.

Host Defense Against Tumors (Tumor Immunity)

ایمونولوژی سرطان پزشکی -آذرماه 1387.

Cancer and the Immune System

Critical Reviews in Oncology / Hematology

Cancer and the Immune System

Figure 1 Key elements of cancer-related inflammation

Volume 1, Issue 5, Pages (November 2007)

Tumor Immunology Ali Al Khader, MD Faculty of Medicine

Figure 2 Neoantigen presentation in the tumour microenvironment

Figure 1 Four nodes to target when inducing anti-tumour immunity

Fig. 2. The AngII/AT1R axis regulates the tumor stroma and contributes to an immunosuppressive microenvironment. The AngII/AT1R axis regulates the tumor.

Cancer Immunotherapy by Dendritic Cells

Heating is a multifunctional adjuvant that affects tumor microenvironment through several intrinsic and extrinsic mechanisms, which could enhance immunotherapy.

Figure 2 Peptide vaccination using TAA-derived long peptides

Antibody-modified T cells: CARs take the front seat for hematologic malignancies by Marcela V. Maus, Stephan A. Grupp, David L. Porter, and Carl H. June.

Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs

Differentiation and Functions of CD8+ Effector T Cells

Schematic diagram outlining the antitumor activity and abscopal effect in combining checkpoint inhibitors with radiation-induced immune response. Schematic.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Markers of cancer cell and lymphocytes in inflammatory infiltration around a tumour as potential markers of immunomodulatory treatment response. Markers.

by Edward S. Morris, Kelli P. A. MacDonald, and Geoffrey R. Hill

Figure 4 Combination immunotherapeutic approaches with imatinib

Colorectal cancer vaccines: Principles, results, and perspectives

Nat. Rev. Urol. doi: /nrurol

Laurence Zitvogel, Guido Kroemer Cancer Cell

Figure 3 The yin and yang of tumour-associated

Potential mechanisms of therapeutic synergy between epigenetic modulation and PD-1 pathway blockade. Potential mechanisms of therapeutic synergy between.

Figure 2 Approaches to improve CAR-T-cell therapy

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

Low-dose cyclophosphamide (Cy) reduces intratumoral Treg numbers and promotes enhanced T-cell trafficking and activation within the tertiary lymphoid aggregates.

Figure 2 Effects of imatinib on components of the anticancer immunosurveillance system Figure 2 | Effects of imatinib on components of the anticancer immunosurveillance.

Mechanisms of immune escape in the tumor microenvironment.

Figure 2 Dominance of the cell-extrinsic effects of autophagy

Host Immune Response to Infection and Cancer: Unexpected Commonalities

Mechanism of CTLA-4-induced immunosuppression.

Jonathan H. Esensten, MD, PhD, Yannick D. Muller, MD, PhD, Jeffrey A

The Tim-3 pathway in cancer.

Figure 3 Tumours secrete factors that cause systemic immunosuppression

Jürgen C. Becker, David Schrama Journal of Investigative Dermatology

Nat. Rev. Urol. doi: /nrurol

Tumor Immunology Ali Al Khader, MD Faculty of Medicine

Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance Laurence Zitvogel, Lorenzo Galluzzi, Mark J. Smyth,

Macrophage Classes and Roles in Immunity

Frequency and kinetics of killer cell apoptosis are dependent on functional conjugations with multiple NALM-6 tumor cells. Frequency and kinetics of killer.

Volume 151, Issue 2, Pages (August 2016)

Interacting MDSCs and mast cells (MC) in human colon carcinoma and in the colon of AOM/DSS-induced tumor-bearing mice. Interacting MDSCs and mast cells.

Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4.

Specificity of HOM-MEL-40/SSX2 p stimulated CD8+ T-cells.

Adaptive NK cells resist immunosuppression in the tumor microenvironment. Adaptive NK cells resist immunosuppression in the tumor microenvironment. FACS-sorted.

Conversion of CD11bhighCD27high NK cells into MDSCs leads to CD11bhighCD27high and CD11bhighCD27low NK cell reduction. Conversion of CD11bhighCD27high.

Geographic colocalization of PD-L1+ tumor cells with infiltrating immune cells in MCC. The predominant pattern of tumor cell PD-L1 expression is at the.

Treatment with R848 and anti-CD200R leads to changes in the composition of intratumor myeloid cells. Treatment with R848 and anti-CD200R leads to changes.

Induction of cytotoxic activity in humanized SCC3 tumor-bearing mice treated with anti-PD-1 antibody. Induction of cytotoxic activity in humanized SCC3.

CDN–treated MOC1 tumors demonstrate enhanced activation of innate and antigen-specific adaptive immunity. CDN–treated MOC1 tumors demonstrate enhanced.

DAC treatment alters immune cell composition and enhances cytokine production in the peritoneal lavage. DAC treatment alters immune cell composition and.

Immunophenotypic analysis of TILs in B16 and K1735 melanoma following combination therapy with antibodies targeting PS and PD-1. Immunophenotypic analysis.

Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)

Immunotherapy of NK-92-S3KD increases anticancer effector productions in HepG2-bearing mice. Immunotherapy of NK-92-S3KD increases anticancer effector.

Immune escape mechanisms in cancer.

Combination of R848 and anti-CD200R affects activation of tumor-infiltrating myeloid cells. Combination of R848 and anti-CD200R affects activation of tumor-infiltrating.

Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.

BCMab1 confers Fc-FcγR–dependent antitumor activity through both macrophages and NK cells. BCMab1 confers Fc-FcγR–dependent antitumor activity through.

Cell counts of immune infiltrate and expression of galectin-1 and galectin-3 in the short-, medium-, and long-term survival cohorts. Cell counts of immune.

Phenotypic diversity of less predominant B-lineage clones.

MDSC population in patient peripheral blood.

Cartoon of OV-mediated effects in tumor.

Development and function of MDSCs

Presentation transcript:

Immunological effects of anticancer therapy. Immunological effects of anticancer therapy. Human neoplasms develop in the context of an intimate, bidirectional relationship with the host immune system, which eventually results in the selection of tumor variants displaying reduced antigenicity and adjuvanticity, as well as in the establishment of local and systemic immunosuppressive networks (A). The clinical success of several treatments currently used against solid malignancies (including conventional chemotherapeutics, in red, targeted anticancer agents, in blue, and radiotherapy) depends (at least in part) on their ability to promote therapeutically relevant tumor-targeting immune responses, either as they increase the immunogenicity (antigenicity or adjuvanticity) of malignant cells (“on-target” immunostimulation), or as they interact with immune effectors or immunosuppressive cell populations (“off-target” immunostimulation; B). CTL, CD8+ cytotoxic T lymphocyte; MDSC, myeloid-derived suppressor cell; NK, natural killer; TAM, tumor-associated macrophage; Treg, CD4+CD25+FOXP3+ T. Lorenzo Galluzzi et al. Cancer Immunol Res 2016;4:895-902 ©2016 by American Association for Cancer Research